
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics is a promising biotechnology company that is well-positioned to succeed with its lead candidate, ARD-101, in Phase 3 development for the treatment of hyperphagia associated with PWS. They also have a diverse pipeline including ARD-201, which has the potential to address current limitations of obesity treatments. However, the current clinical hold on the ARD-101 program is a major factor in our Neutral rating.
Bears say
Aardvark Therapeutics is currently facing numerous risks, including potential failure to lift the current clinical hold on ARD-101, negative clinical results from the Phase 3 HERO trial in PWS subjects, and potential partnership and geopolitical risks, which could greatly impact its financials. Additionally, the company's current valuation and price target of $6 per share seems overly optimistic and could be at risk of revision based on downwardly revised probabilities of approval for ARD-101. Overall, until Aardvark Therapeutics can address these risks and demonstrate positive clinical results, it is recommended to maintain a neutral position on the stock.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares